Skip to navigation | Skip to main content | Skip to footer
Menu Search the University of Manchester siteSearch
Search type

Alternatively, use our A–Z index

Dr Andrew Clamp - publications

List of publications

2014

  • Metcalf RL, Fry DJ, Swindell R, McGurk A, Clamp AR, Jayson GC, Hasan J. (2014). Thrombosis in ovarian cancer: a case control study. British Journal of Cancer Management, eScholarID:220127 | DOI:10.1038/bjc.2014.3

2012

  • Quinn AM, Blackhall F, Wilson G, Danson S, Clamp A, Ashcroft L, Brierley J, Hasleton P. (2012). Extrapulmonary small cell carcinoma: a clinicopathological study with identification of potential diagnostic mimics. Histopathology, 61, 454-464. eScholarID:199959

2011

  • O'Connor JPB, Rose CJ, Jackson A, Watson Y, Cheung S, Maders F, Whitcher BJ, Roberts C, Buonacorssi GA, Thompson G, Clamp AR, Jayson GC, Parker GJ. (2011). DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6. Br J Cancer, 105, 139-145. eScholarID:152021 | DOI:10.1038/bjc.2011.191
  • Clamp A. (2011). Endometrial cancer: what have the clinical trials taught us?. In Kehoe S, Edmondson RJ, Gore M, McNeish IA (Ed.), Gynaecological Cancer: Biology and therapeutics. (pp. 153-166). London: RCOG Press. eScholarID:152040
  • Griffiths RW, Zee YK, Evans S, Mitchell CL, Kumaran GC, Welch RS, Jayson GC, Clamp AR, Hasan J. (2011). Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of ovary, peritoneum and fallopian tube. Int J Gynecol Cancer, 21(1), 58-65. eScholarID:152028 | DOI:10.1097/IGC.0b013e3182049273
  • Sabharwal A, Waters R, Danson S, Clamp A, Lorigan P, Thatcher N, Margison GP, Middleton MR. (2011). Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mononuclear cells. Melanoma Res, 21, 502-508. eScholarID:1d20887 | DOI:10.1097/CMR.0b013e32832ccd58

2009

  • Kumaran GC, Jayson GC, Clamp AR. (2009). Antiangiogenic drugs in ovarian cancer. Br J Cancer, 100(1), 1-7. eScholarID:1d32387 | DOI:10.1038/sj.bjc.6604767

2008

  • Clamp, A, Schoffski, P, Valle, J, Wilson, R, Marreaud, S, Govaerts, A, Debois, M, Lacombe, D, Twelves, C, Chick, J, Jayson, G, NULL. (2008). A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer. Cancer Chemother Pharmacol, 61(4), 579-585. eScholarID:1d31262 | DOI:10.1007/s00280-007-0509-5
  • Clamp AR, Jayson GC. (2008). The role of imaging in the clinical development of anti-angiogenic agents. In Teicher BV, Ellis L (Ed.), Antiangiogenic agents in cancer therapy. Humana Press. eScholarID:152047
  • Rosa DD, Clamp AR, Jayson GC. (2008). Tumours of the ovary and fallopian tube. In Price P, Sikora K, Illidge T (Ed.), Treatment of cancer. (pp. 748-763). London: Hodder Arnold. eScholarID:152053

2007

  • Backen A, Cole C, Lau S, Clamp A, McVey R, Gallagher JT, Jayson GC. (2007). Heparan sulphate synthetic and editing enzymes in ovarian cancer. Br J Cancer, 96(10), 1544-1548. eScholarID:1d31280 | DOI:10.1038/sj.bjc.6603747
  • Rosa, D, Ton, N, Clamp, A, Mullamitha, S, Lau, S, Clayton, R, Kitchener, HC, Shanks, J, McVey, R, Jayson, G-. (2007). The neoadjuvant approach in the treatment of patients with advanced epithelial ovarian carcinoma. Clin Oncol (R Coll Radiol), 19(2), 125-128. eScholarID:1d31282 | DOI:10.1016/j.clon.2006.11.015

2006

  • Baka S, Clamp A, Jayson GC. (2006). A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis. Expert Opin Ther Targets, 10(6), 867-876. eScholarID:1d30905 | DOI:10.1517/14728222.10.6.867
  • Clamp, A, Blackhall, FH, Blackhall, F, Henrioud, A, Jayson, G-, Javaherian, K, Esko, J, Gallagher, J, Gallagher, JT, Merry, C. (2006). The morphogenic properties of oligomeric endostatin are dependent on cell surface heparan sulfate. J Biol Chem, 281(21), 14813-14822. eScholarID:1d30264 | DOI:10.1074/jbc.M512400200

2005

  • Hasan, J, Shnyder, S, Clamp, A, McGown, A, Bicknell, R, Presta, M, Bibby, M, Double, J, Craig, S, Leeming, D, Stevenson, K, Gallagher, JT, Jayson, G-. (2005). Heparin octasaccharides inhibit angiogenesis in vivo. Clin Cancer Res, 11( 22), 8172-9. eScholarID:1d12942 | DOI:10.1158/1078-0432.CCR-05-0452
  • Hasan J, Ton N, Mullamitha S, Clamp A, McNeilly A, Marshall E, Jayson G-. (2005). Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer. Br J Cancer, 93( 6), 647-51. eScholarID:1d31099
  • Clamp A, Jayson G-. (2005). Profiling heparan sulfate proteoglycans in ovarian carcinoma. ScientificWorldJournal, 5, 230-3. eScholarID:1d30760 | DOI:10.1100/tsw.2005.31
  • Whitworth, M, Backen, A, Clamp, A, Wilson, G, McVey, R, Friedl, A, Rapraeger, A, David, G, McGown, A, Slade, R, Gallagher, JT, Jayson, G-. (2005). Regulation of fibroblast growth factor-2 activity by human ovarian cancer tumor endothelium. Clin Cancer Res, 11( 12), 4282-8. eScholarID:1d11457 | DOI:10.1158/1078-0432.CCR-04-1386
  • Clamp A, Jayson G-. (2005). The clinical potential of antiangiogenic fragments of extracellular matrix proteins. Br J Cancer, 93( 9), 967-72. eScholarID:1d30757

2004

  • Clamp, A, Adams, M, Atkinson, R, Boven, E, Calvert, A, Cervantes, A, Ganesan, T, Lotz, J, Vasey, P, Cheverton, P, Jayson, G-. (2004). A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer. Gynecol Oncol, 95( 1), 114-9. eScholarID:1d9249 | DOI:10.1016/j.ygyno.2004.06.047

2003

  • Clamp A, Blackhall FH, Vasey P, Soukop M, Coleman R, Halbert G, Robson L, Jayson G-. (2003). A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma. Br J Cancer, 89( 7), 1152-4. eScholarID:1d9251
  • Danson, S, Lorigan, P, A. Arance, Clamp, A, Ranson, MR, J. Hodgetts, L. Lomax, L. Ashcroft, Thatcher, N, M.R. Middleton. (2003). Randomized Phase II Study of Temozolomide Given Every 8 Hours or Daily With Either Interferon Alfa-2b or Thalidomide in Metastatic Malignant Melanoma. Journal of Clinical Oncology, July, eScholarID:1d25113 | DOI:10.1200/JCO.2003.10.039

2002

  • Clamp A, Jayson G-. (2002). The clinical development of the bryostatins. Anticancer Drugs, 13, eScholarID:1d2165
  • Clamp A, Jayson G-. (2002). Weekly platinum chemotherapy for recurrent ovarian cancer. Br J Cancer, 86, eScholarID:1d2167